Q3FY19 : Dr Lal Path Labs net profit jumps 27 per cent

 Diagnostics player Dr. Lal Path Labs net profit came in at Rs. 46.1 crore with an EPS of Rs. 5.55 per share  as against Rs. 36.3 crore with an EPS of Rs. 4.39  per share with the PAT margins rising  to 15.8 per cent from 13.8 per cent for the corresponding period last year.

The company’s revenues came in at Rs. 292.5 crore, up 11.3 per cent YoY from Rs. 262.7 crore for the corresponding period last year on the back of 12.1 per cent increase in patient volumes. The number of patients tested stood at 4.3 million in Q3.The company continues to deliver volume growth via heightened brand interaction and introduction of new high end tests.

The company’s EBITDA came in at Rs. 65.6 crore for the quarter ended December 2018, registering a growth of 15.9 per cent from Rs. 56.6 crore in the corresponding quarter last year.

The company introduced high end tests under the brand name of Neuro pro and Onco pro. The company increased interaction with its customers through both digital and online mediums which led to higher walk-ins.

The company management believes that consistent service delivery and patient engagement will play a key role in the future for the company.

On Friday, Dr. Lal Path Labs closed at Rs. 1077.9 per share, down 1.09 per cent  on the BSE.